Vimarsana
Biggest News Aggregation in the World

Page 6 - Patrick Bursey News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Patrick Bursey. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Patrick Bursey Today - Breaking & Trending Today

OncoSec Enters into Option Agreement with Sirtex Medical to Co-Promote TAVO™ - Vimarsana News

OncoSec Enters into Option Agreement with Sirtex Medical to Co-Promote TAVO™

Share this article Share this article PENNINGTON, N.J. and SAN DIEGO, Jan. 19, 2021 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec") today announced it entered into an agreement with Sirtex Medical, Inc. (Sirtex) granting Sirtex an option to non-exclusively co-promote the Company's lead product candidate, TAVO™ (tavokinogene telseplasmid) in anti-PD-1 checkpoint refractory metastatic melanoma in the U.S. By entering into this co-promotion, OncoSec intends to capitalize on both the extensive experience Sirtex has in marketing drug/device combination pro...

OncoSec Announces First Patient Dosed in Phase 2 Trial of TAVO™ Plus OPDIVO® as Neoadjuvant Therapy for Melanoma - Vimarsana News

OncoSec Announces First Patient Dosed in Phase 2 Trial of TAVO™ Plus OPDIVO® as Neoadjuvant Therapy for Melanoma

OncoSec Announces First Patient Dosed in Phase 2 Trial of TAVO™ Plus OPDIVO® as Neoadjuvant Therapy for Melanoma News provided by Share this article Share this article PENNINGTON, N.J. and SAN DIEGO, Jan. 8, 2021 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec") today announced the first patient was dosed in OMS-104, an investigator-initiated Phase 2 trial evaluating TAVO™ (tavokinogene telseplasmid), the Company's intratumoral DNA plasmid-based interleukin-12 (IL-12) therapy administered using its gene delivery platform (gene electrotransfer), in co...

Ziopharm Oncology Announces Clearance of Taiwan's First IND of Non-viral CAR-T for the ... - Vimarsana News

Ziopharm Oncology Announces Clearance of Taiwan's First IND of Non-viral CAR-T for the ...

Press release content from Globe Newswire. The AP news staff was not involved in its creation. Ziopharm Oncology Announces Clearance of Taiwan’s First IND of Non-viral CAR-T for the ... ZIOPHARM Oncology IncDecember 21, 2020 GMT – Advances Eden BioCell’s clinical program to validate Rapid Personalized Manufacturing (RPM) – – Clinical trial to study autologous CD19-specific CAR-T using RPM technology designed to reduce cost and simplify production for infusion the day after gene transfer – BOSTON, Dec. 21, 2020 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (“Ziopharm” or “the C...

Source: apnews.com
Avadel Pharmaceuticals Announces Submission of New Drug Application for FT218 to the FDA - Vimarsana News

Avadel Pharmaceuticals Announces Submission of New Drug Application for FT218 to the FDA

Share: DUBLIN, Ireland, Dec. 16, 2020 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (NASDAQ:AVDL) today announced the submission of its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for FT218, an investigational, once-nightly formulation of sodium oxybate designed to treat excessive daytime sleepiness and cataplexy in adults with narcolepsy. "The submission of our NDA represents a significant milestone for the Company. We look forward to working with the FDA during the NDA review process in order to get once-nightly FT218 approved and commercially available to ...